Human regulatory T cells (Treg) equally potent immune suppression. Thus, CD39 surface marker can be successfully used for routine isolation of functionally-active human Treg from the peripheral blood of healthy donors or patients with cancer for studies of their role in health and disease.
Introduction
Human thymus-derived natural regulatory T cells (nTreg) play a key role in maintaining tolerance (Strauss et al., 2007a) . nTreg represent only a small subset of CD4 + T lymphocytes in the peripheral circulation and are responsible for the balance of immune responses, which is essential for health (Sakaguchi and Sakaguchi, 2005) . nTreg excess or loss is associated with disease. Their accumulations in patients with cancer suppress anti-tumor immunity and promote tumor progression, while autoimmune diseases are associated with a decrease in the number and/or function of nTreg (Sakaguchi et al., 1985; Asano et al., 1996; Woo et al., 2001; Liyanage et al., 2002; Strauss et al., 2007a,b) . The role of nTreg in transplant tolerance and graft-versus-host disease (GVHD) is being extensively investigated (Coghill et al., 2008) . Studies of human nTreg have been limited, largely because of their considerable diversity and a lack of a unique surface marker(s) that would allow for their isolation and purification. Consequently, much of the current knowledge about nTreg is derived from murine models, which offer an ample opportunity for nTreg isolation in numbers sufficient for functional studies, nTreg adoptive transfers or their depletion Nagahama et al., 2007; Curiel, 2008) . However, it appears that extrapolation from murine to human nTreg is not always accurate, and that human nTreg might be more heterogenous or utilize somewhat different mechanisms of suppression than their murine counterparts (Ziegler, 2006) . Hence, there is a need for nTreg isolation and characterization from human body fluids and tissues to be able to evaluate their contribution to the control of beneficial as well as disease-associated immune responses. (Jonuleit et al., 2001; Levings et al., 2001; Dieckmann et al., 2001) . More recently, with the realization that suppression mediated by Treg is regulated by the forkhead transcription factor (FOXP3), this protein has been widely considered as an identity marker for Treg. However, it has been reported that FOXP3 expression is not restricted to Treg, as activated T cells as well as tumor cells may be FOXP3 + (Morgan et al., 2005; Ziegler, 2006; Karanikas et al., 2008) . For the purpose of Treg isolation, FOXP3 is not useful, because it is an intracytoplasmic protein (Zhang and Zhao, 2007) . We and others have largely depended on the isolation of CD4 + CD25 + T cells as Treg, using immunobead-based separation methods (Jeal, 2008 Recently, the presence on nTreg of CD39, a rate-limiting ectonucleotidase responsible for enzymatic cleavage of adenosine triphosphate (ATP) to adenosine monophosphate (AMP), has been reported on the surface of murine and human nTreg (Deaglio et al., 2007; Borsellino et al., 2007) . In this communication, we show that CD39 is a surface marker that can be successfully and reliably used for isolation from the peripheral blood of functionally-active human nTreg. The capability to obtain purified nTreg is essential for establishing their role in human health and disease.
Materials and methods

Healthy volunteers and cancer patients
Venous peripheral blood samples were obtained from 15 healthy donors (NC) as well as 15 patients with head and neck squamous cell carcinoma (HNSCC). All subjects signed an informed consent approved by the Institutional Review Board of the University of Pittsburgh. The NC group included 4 males and 11 females with a mean age of 39 years (range, 24 to 58 years). The patients with HNSCC were age-matched with NC and included 10 males and 5 females. All had active disease and were not previously treated with oncologic therapy.
Collection of peripheral blood mononuclear cells (PBMC)
Blood samples (20-30 mL) were drawn into heparinized tubes and centrifuged on Ficoll-Hypaque gradients (GE Healthcare Bioscience). PBMC were recovered, washed in AIM-V medium (Invitrogen), counted in a trypan blue dye and immediately used for experiments. 
Separation of Treg
Antibodies
The following anti-human monoclonal antibodies were used for staining or cell sorting: anti-CD3-ECD, anti-CD4-ECD, anti-CD4-PC5, anti-CD8-PC5, anti-CD25-PC5, anti-GITR-FITC, anti-FOXP3-FITC, anti-CD39-FITC, anti-CD39-PE, anti-CD26-PE and anti-CTLA4-PE. Antibodies and appropriate isotypes, which served as negative controls for surface as well as intracellular staining, were purchased from Beckman Coulter. Anti-FOXP3, anti-CD39-FITC and anti-CD39-PE were purchased from eBioscience. All antibodies were pre-titered on human T cells to determine optimal staining dilutions.
Surface and intracellular staining
Freshly isolated or activated cells were stained for flow cytometry as previously described (Strauss et al., 2007a,b) . Briefly, for staining of surface markers, cells were incubated with the relevant pre-titered antibodies for 30 min at 4°C in the dark and then fixed with 2% (w/v) paraformaldehyde for 15 min. For intracellular staining, cells were additionally permeabilized with 0.1% (w/v) saponin and stained with antibodies specific for intracellular markers for 30 min at 4°C in the dark. Cells were washed twice with 0.1% saponin in PBS, resuspended in a flow solution and immediately analyzed by flow cytometry. Appropriate isotype controls were included for each sample.
Flow cytometry
Flow cytometry was performed using a EPICS® XL-MCL flow cytometer equipped with Expo32 software (Beckman Coulter). Lymphocyte were identified based on characteristic properties of the cells in the forward (FSC) and side scatter (SSC). FSC and SSC were set in a linear scale, and 10 5 cells were acquired for analysis, which was performed using the Coulter EXPO 32vl. bated in wells of flat-bottom 96-well plates at RC/suppressor (S) ratios of 1:1, 2:1, 5:1 and 10:1. RC were stimulated with plate-bound OKT-3 (2 µg/mL) and soluble anti-CD28 mAb (2 µg/mL) (Miltenyi) in the presence of 150 IU/mL IL-2 for 5 days. S cells were considered to mediate suppression, when they significantly inhibited proliferation of RC in co-culture assays. All CFSE data were analyzed using the ModFit software provided by Verity Software (Topsham). The percentage of suppression was calculated by using the mean proliferation index (PI) of RC alone compared to the PI of cultures containing RC +S cells. The program determines the percentage of cells within each detected peak, whereas the sum of all peaks in the control culture is set to be 100% proliferation or 0% suppression.
Statistical analysis
All data were presented as the means of at least three experiments ± 1 standard deviation (SD). The data were analyzed using the paired Student's t test. Spearman correlations were performed to estimate relationships between percentages of T cells positive for a given marker or expression levels (MFI) of these markers. The p values b0.05 were considered to be significant. To examine phenotypic profiles of these Treg subsets following their purification from peripheral blood, multiparameter flow cytometry was performed. The data are mean percentages ± SD (mean cell numbers ± SD are in parentheses) from three representative individuals in each group. The cell numbers were calculated based on 50 × 10 6 PBMC used for each experiment. (Fig. 3B, D (Fig. 3C, D) , although only 50% to 70% of these cells in NC and 50-90% in HNSCC patients were CD25
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high . GITR + cells low expression of CD127 in Treg cells has been recently described and used for Treg isolation (Liu et al., 2006; Hartigan-O'Connor et al., 2007; Peters et al., 2008) . Also, CD26, a widely distributed cell membrane-associated glycoprotein with intrinsic dipeptidyl peptidase IV activity, which is associated with adenosine deaminase in humans has been recently reported by us to be low/absent on Treg (Fig. 3D) . The representative dot blots show that OKT3-activated Treg contained The data are mean percentages ± SD of experiments done with cells from 15 individuals in each group. PBMC were stained using antibodies for surface or intracellular markers. Cells were analyzed on flow cytometry. The asterisks indicate significant differences (p ≤ 0.05) between both groups. suppression data for one NC and one HNSCC patient are shown in Fig. 4A , B. While all three Treg subsets mediated suppression of RC proliferation, CD4 + CD25 + T cells obtained from NC were only weakly suppressive. In patients with cancer, suppression levels mediated by all three subsets were much higher (Fig. 4B) . In NC and patients with cancer, suppression activity linearly decreased upon S cell dilution (Fig. 4C, D (Fig. 4) . Single-cell sorted CD4 + CD39 neg cells did not mediate suppression of RC proliferation (data not shown).
Discussion
To date, most investigators have utilized FOXP3 as a "benchmark" for human Treg despite the newly available information that transient expression of this transcription factor occurs in non-regulatory activated T cells (Ziegler, 2006; Mottet and Goishayan, 2007; Roncarolo and Gregori, 2008; Ahmadzdeh et al., 2008) . Also, FOXP3 is not expressed in all Treg and, more importantly, is not a cell surface molecule. Therefore, it cannot be used for isolation of human Treg. Another surface marker, CD25 (a high affinity IL-2Rα) has been adopted for this purpose, based on the rationale that all Treg are dependent on IL-2 for their function and expansion (Fontenot et al., 2005; Bayer et al., 2007 quantitative flow cytometry has been largely arbitrary and inconsistent, as no definite expression criteria have been so far defined for the "high" CD25 expression level on CD4 + T cells. In view of this unsatisfactory situation, which is exacerbated by the differences that seem to exist between murine and human Treg, there is an urgent need for a more stringent and effective strategy of Treg isolation in humans.
The recent identification of a new surface marker, CD39 ectonucleotidase, for the isolation and characterization of human Treg is a highly desirable development. The advantage of this marker is that it recognizes Treg with suppressor activity mediated via pericellular adenosine, which is the end product of enzymatic degradation of ATP (Robson et al., 2006) . Thus, CD39 defines Treg based not only on the phenotypic but also functional characteristics. Also, CD39 expression on Treg is associated with that of another enzyme, ecto-5″neuleotidase or CD73, which mediates cleavage of AMP to adenosine. Adenosine has been considered to be a strong suppressor of T cell functions (Zarek & Powell, 2007) . However, before this new surface membrane-associated enzyme can be accepted as the Treg marker, it is necessary to consider properties of the T cell subset it defines relative to those of widely used CD4 (Strauss et al., 2007a,b) . The overlapping expression of CD39 and CD25 high markers on Treg in the peripheral circulation of NC and patients with cancer supports the conclusion that these CD4 + T cell subsets, although not identical, represent highly-enriched populations of suppressor T cells.
In aggregate, the presented data indicate that the immunobead method for human CD39 + Treg isolation from the peripheral blood of NC or patients with cancer consistently yields Treg with a high purity and strong suppressor function.
